Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Encouraging new drug development

Encouraging new drug development

BETHESDA, Md. - At its latest meeting last week, the National Task Force on AIDS Drug Development focused on incentives and disincentives for private investment and collaboration in drug discovery and development for HIV, AIDS and other life-threatening diseases.

Although the task force staff compiled a lengthy laundry list of potential incentives, panel members raised other issues, in particular third-party reimbursement for off-label use of therapies. Participants agreed that expansion of reimbursement for off-label indications would promote drug development.

Tim Westmoreland, a representative of the Pediatric AIDS

Read the full 899 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE